SK140099A3 - 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds - Google Patents

5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds Download PDF

Info

Publication number
SK140099A3
SK140099A3 SK1400-99A SK140099A SK140099A3 SK 140099 A3 SK140099 A3 SK 140099A3 SK 140099 A SK140099 A SK 140099A SK 140099 A3 SK140099 A3 SK 140099A3
Authority
SK
Slovakia
Prior art keywords
phenyl
amino
pyrido
pyrimidine
pyridinyl
Prior art date
Application number
SK1400-99A
Other languages
English (en)
Slovak (sk)
Inventor
Shripad S Bhagwat
Richard J Perner
Yu Gui Gu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of SK140099A3 publication Critical patent/SK140099A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK1400-99A 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds SK140099A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84348497A 1997-04-16 1997-04-16
PCT/US1998/007201 WO1998046604A1 (en) 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds

Publications (1)

Publication Number Publication Date
SK140099A3 true SK140099A3 (en) 2000-05-16

Family

ID=25290123

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1400-99A SK140099A3 (en) 1997-04-16 1998-04-13 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds

Country Status (19)

Country Link
EP (1) EP0975633A1 (ja)
JP (1) JP2001520654A (ja)
KR (1) KR20010006462A (ja)
CN (1) CN1252069A (ja)
AR (1) AR012437A1 (ja)
AU (1) AU741033B2 (ja)
BG (1) BG103853A (ja)
BR (1) BR9809056A (ja)
CA (1) CA2286592A1 (ja)
CO (1) CO4940470A1 (ja)
HU (1) HUP0001443A3 (ja)
IL (1) IL131617A0 (ja)
NO (1) NO995035L (ja)
NZ (1) NZ337125A (ja)
PL (1) PL336265A1 (ja)
SK (1) SK140099A3 (ja)
TR (1) TR199902550T2 (ja)
WO (1) WO1998046604A1 (ja)
ZA (1) ZA983175B (ja)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001057040A1 (en) * 2000-02-03 2001-08-09 Abbott Laboratories 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
CA2434834C (en) 2001-02-12 2010-09-14 F. Hoffmann-La Roche Ag 6-substituted pyrido-pyrimidines
CN107744520A (zh) * 2017-10-25 2018-03-02 南京多宝生物科技有限公司 嘧啶类化合物在制备促进小肠蠕动药物中的应用
CN112209924B (zh) * 2019-07-09 2022-04-05 中国科学院天津工业生物技术研究所 选择性腺苷a1受体拮抗剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB774094A (en) * 1953-01-02 1957-05-08 Wellcome Found Improvements in or relating to pyrimidine compounds
IL112249A (en) * 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds

Also Published As

Publication number Publication date
CA2286592A1 (en) 1998-10-22
EP0975633A1 (en) 2000-02-02
TR199902550T2 (xx) 2000-04-21
KR20010006462A (ko) 2001-01-26
ZA983175B (en) 1998-10-21
PL336265A1 (en) 2000-06-19
JP2001520654A (ja) 2001-10-30
BR9809056A (pt) 2000-08-01
CO4940470A1 (es) 2000-07-24
CN1252069A (zh) 2000-05-03
AR012437A1 (es) 2000-10-18
BG103853A (en) 2000-06-30
AU741033B2 (en) 2001-11-22
NO995035L (no) 1999-12-15
AU7108098A (en) 1998-11-11
NZ337125A (en) 2001-06-29
HUP0001443A3 (en) 2001-01-29
HUP0001443A2 (hu) 2000-10-28
WO1998046604A1 (en) 1998-10-22
IL131617A0 (en) 2001-01-28
NO995035D0 (no) 1999-10-15

Similar Documents

Publication Publication Date Title
US5665721A (en) Heterocyclic substituted cyclopentane compounds
US8026246B2 (en) Aurora kinase inhibitors for inhibiting mitotic progression
WO2000023444A1 (en) 5,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
KR20080080584A (ko) ｃ-Ｍｅｔ의 억제제 및 이의 용도
CZ20021220A3 (cs) Aminotriazolopyridinové deriváty
JP2011529918A (ja) Ｊａｋ３阻害剤としてのピペリジン誘導体
EP1575951B1 (en) Heterocyclic compounds, methods of making them and their use in therapy
CN111039946A (zh) 一类咪唑并芳环类化合物的制备和应用
SK141799A3 (en) 5,7-disubstituted 4-aminopyrido[2,3-d]pyrimidine compounds and their use as adenosine kinase inhibitors
US20210040066A1 (en) Tetrahydroisoquinoline compound, preparation method therefor, pharmaceutical composition containing same, and use thereof
EP3418277B1 (en) Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof
WO2005058315A1 (en) Novel heterocyclic compounds as ikk2 inhibitors with anti-hbv activity
SK140099A3 (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds
SK142099A3 (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
US6030969A (en) 5,6,7-trisubstituted-4-aminopyrido[2,3-D] pyrimidine compounds
WO2001057040A1 (en) 6,7-disubstituted-4-aminopyrido[2,3-d]pyrimidine compounds
CZ350899A3 (cs) 5,6,7-trisubstituované-4-aminopyrido-[2,3- D]pyrimidinové sloučeniny
MXPA99009512A (en) 5,6,7-trisubstituted-4-aminopyridol[2,3-d]pyrimidine compounds
CZ360199A3 (cs) Sloučeniny 6,7-disubstituovaného-4- aminopyrido [2,3-dJ pyrimidinu
CZ339399A3 (cs) 5,7-Disubstituované 4-aminopyrido[2.3- D]pyrimidinové sloučeniny a jejich použití jako inhibitorů adenosin kinasy
CN117362323A (zh) 一类prmt5抑制剂及其用途
AU2002232346A1 (en) 2-arylamino-pyrimidines for the treatment of GSK3-related disorders